artus CMV RGQ MDx Kit and artus CMV QS-RGQ MDx Kit

Cytomegalovirus (cmv) Dna Quantitative Assay

FDA Premarket Approval P130027 S004

This medical device record is a pma supplement. A supplement may have changed the device description/function or indication from that approved in the original pma. Be sure to look at the original pma record for more information.

Pre-market Approval Supplement Details

Approval for relocation of a manufacturing process.

Deviceartus CMV RGQ MDx Kit and artus CMV QS-RGQ MDx Kit
Classification NameCytomegalovirus (cmv) Dna Quantitative Assay
Generic NameCytomegalovirus (cmv) Dna Quantitative Assay
ApplicantQIAGEN, INC.
Date Received2017-07-28
Decision Date2018-03-13
PMAP130027
SupplementS004
Product CodePAB
Advisory CommitteeMicrobiology
Supplement Type135 Review Track For 30-day Notice
Supplement ReasonProcess Change - Manufacturer/sterilizer/packager/supplier
Expedited ReviewNo
Combination Product No
Applicant Address QIAGEN, INC. qaigen Strasse 1 40724 hilden 40724

Supplemental Filings

Supplement NumberDateSupplement Type
P130027Original Filing
S006 2018-08-30 30-day Notice
S005 2018-03-08 30-day Notice
S004 2017-07-28 135 Review Track For 30-day Notice
S003 2017-06-29 Normal 180 Day Track
S002 2016-11-14 Normal 180 Day Track
S001 2015-06-12 30-day Notice

NIH GUDID Devices

Device IDPMASupp
04053228024538 P130027 000
04053228002086 P130027 000
© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.